ReAlta Life Sciences
Norfolk, US · Founded 2017 · Delaware corporation
ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
BiotechHealthtech
Founders & leadership
NK
Neel KrishnaExecutive Officer
KC
Kenji CunnionExecutive Officer
JR
John RickmanExecutive Officer
PM
Paolo MartiniExecutive Officer
DM
David MarekExecutive Officer, Director
UT
Ulrich ThienelDirector
JN
Jerry NadlerDirector
TK
Thomas Kerry McCarterManaging Director
JH
John HardingDirector
AM
Andrew MillerDirector
MA
Mert AktarDirector
LW
Lewis WilliamsDirector
Competitors · 5
by search overlapPatSnap86 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Cowles_Investments_StemCentrx48 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Mapquest34 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Diabetes Prevention Program34 shared keywords
Eli Lilly33 shared keywords
Companies competing with ReAlta Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$29.9MraisedMay 2025 · 149 investors · BiotechnologyRule 506(b)
▶$29.9MraisedMay 2025 · 149 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John RickmanExecutive Officer
- Andrew MillerDirector
- Neel KrishnaExecutive Officer
- Lewis WilliamsDirector
- Frank GadamsDirector
- Kenji CunnionExecutive Officer
- Paolo MartiniExecutive Officer
- Mert AktarDirector
- Edward Heidt, Jr.Director
- Laurie GlimcherDirector
- Christi ShawDirector
- David MarekExecutive Officer, Director
- Emma ReeveDirector
- Offering amount
- $30M
- Amount sold
- $29.9M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2025 · 109 investors · BiotechnologyRule 506(b)
▶$25MraisedMay 2025 · 109 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurie GlimcherDirector
- David MarekExecutive Officer, Director
- Edward Heidt, Jr.Director
- Lewis WilliamsDirector
- Andrew MillerDirector
- Kenji CunnionExecutive Officer
- John RickmanExecutive Officer
- Frank GadamsDirector
- Paolo MartiniExecutive Officer
- Emma ReeveDirector
- Mert AktarDirector
- Christi ShawDirector
- Neel KrishnaExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMay 2025 · 85 investors · BiotechnologyRule 506(b)
▶$12MraisedMay 2025 · 85 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MillerDirector
- Paolo MartiniExecutive Officer
- Frank GadamsDirector
- Laurie GlimcherDirector
- John RickmanExecutive Officer
- David MarekExecutive Officer, Director
- Mert AktarDirector
- Neel KrishnaExecutive Officer
- Lewis WilliamsDirector
- Kenji CunnionExecutive Officer
- Christi ShawDirector
- Emma ReeveDirector
- Edward Heidt, Jr.Director
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedSep 2023 · 92 investors · BiotechnologyRule 506(b)
▶$22.5MraisedSep 2023 · 92 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Director
- Deborah GeraghtyDirector
- Jonathan ZalevskyDirector
- Christine NeikirkDirector
- John RickmanExecutive Officer
- Neel KrishnaExecutive Officer
- Azmi NabulsiDirector
- Kathryn AbshireExecutive Officer
- Barry StrasnickDirector
- Ulrich ThienelExecutive Officer, Director
- Frank GadamsDirector
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedFeb 2020 · PharmaceuticalsRule 506(b)
▶$2MofferedFeb 2020 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Executive Officer, Director
- Thomas Kerry McCarterExecutive Officer
- Jonathan ZalevskyDirector
- Azmi NabulsiDirector
- Deborah GeraghtyDirector
- Frank GadamsDirector
- Barry StrasnickDirector
- Christine NeikirkDirector
- John RickmanExecutive Officer
- Neel KrishnaExecutive Officer
- Ulrich ThienelExecutive Officer, Director
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $2M
- Minimum investment
- $75K
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$12MofferedOct 2019 · PharmaceuticalsRule 506(b)
▶$12MofferedOct 2019 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ulrich ThienelExecutive Officer, Director
- Kenji CunnionExecutive Officer, Director
- Neel KrishnaExecutive Officer
- John HardingExecutive Officer, Director
- Barry StrasnickDirector
- Edward Heidt, Jr.Director
- Frank GadamsDirector
- Thomas Kerry McCarterExecutive Officer
- John RickmanExecutive Officer
- Offering amount
- $12M
- Proceeds to insiders
- $619K
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.8MraisedSep 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedSep 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward Heidt, Jr.Director
- Ulrich ThienelDirector
- Jerry NadlerDirector
- Neel KrishnaExecutive Officer
- Thomas Kerry McCarterExecutive Officer
- John HardingDirector
- Kenji CunnionExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $4.8M
- Proceeds to insiders
- $14K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.